开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2022-08-13 Yancie JAY

请问各位前辈，如果文章字数超出范围会被直接拒稿吗

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2019-05-11 haiyang0518

审稿速度:1.0 | 投稿命中率:25.0
经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，

161 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2023-03-16 1e16a6dfm27(暂无匿称) 来自北京

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：免疫
经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！
2022，July 7， submitted

July 12， under review

July 18，Required Reviews Completed

July 19，under review

July 25，under review

July 27，Required Reviews Completed

Jul 31, Revise

Sep 07， Revision Submitted to the journal
Sep 07，With Editor
Sep 07，under review

Sep 18, 2022 Required Reviews Completed

Sep 29, 2022 Revise

Oct 29, 2022 Revision Submitted to Journal

Oct 30, 2022 With Editor

Nov 06, 2022 under review

Nov 07, 2022 Required Reviews Completed

Nov 08, 2022 编辑发邮件让修改参考文献格式

Nov 09, 2022 Accept

216 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2016-03-14 刘洋1981

你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表::
我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右

fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右

251 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2024-04-09 ms6000001986535996 来自上海

审稿速度:2.0
经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉

83 0

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2024-03-29 ms3000000561056569 来自辽宁省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：经过了圣诞节，实际上可能只用了三周返回稿件

96 0

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2023-12-11 ms1000000959787142 来自天津

各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢

98 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2022-10-20 y-y-y

审稿速度:2.0
偏重的研究方向：转化医学;临床转化
经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。

212 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2024-01-17 ms2000000395345853 来自四川省

偏重的研究方向：转化医学
经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢

103 0

[GetPortalCommentsPageByObjectIdResponse(id=1238468, encodeId=2177123846800, content=请问各位前辈，如果文章字数超出范围会被直接拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Sat Aug 13 13:18:38 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570750, encodeId=5e1b5e07504d, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：20190326投稿，20190410回复一审意见，20190425修回，20190510正式接受，一共45天，很快了，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKuTLzo0HrCp5RQZ4fKPw3icrAGelOfQHYnzrHTyBM5S7iaNGibGB6JLrnicGIauO7fGUKSibz9t14Nf6w/132, createdBy=82c02152739, createdName=haiyang0518, createdTime=Sat May 11 09:13:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119888, encodeId=b16b21198880e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：审稿速度很快，编辑很nice，审稿人要求也比较高，补了两轮实验。Finally accept！分享我文章的状态，希望对大家有帮助！ 2022，July 7， submitted July 12， under review July 18，Required Reviews Completed July 19，under review July 25，under review July 27，Required Reviews Completed Jul 31, Revise Sep 07， Revision Submitted to the journal Sep 07，With Editor Sep 07，under review Sep 18, 2022 Required Reviews Completed Sep 29, 2022 Revise Oct 29, 2022 Revision Submitted to Journal Oct 30, 2022 With Editor Nov 06, 2022 under review Nov 07, 2022 Required Reviews Completed Nov 08, 2022 编辑发邮件让修改参考文献格式 Nov 09, 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu Mar 16 09:02:22 CST 2023, time=2023-03-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=520174, encodeId=93705201e435, content=你看上面文章觉得几分的水平，我觉得目前至少完爆SR，你的文章水平你觉得是多少分？这个刊物要求并不低，柳叶刀子刊最差的也是9分，这个新刊今年不会低于5，而且有超过NC的潜力。我们投四大刊悲剧了，都推荐投各自子刊，综合考虑选择了这个，我们文章水平实话说，确实十分以上。fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, beContent=fulin2222 2016-03-14 发表:: 我刚投了一篇，也挺关心的，据有人推测今年好像只有2分左右, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200608/69dd05c9fcfa4768838a5589b5b25dd6/e3def69d3a5a45e8b6b33e44bf34132b.jpg, createdBy=8b9295286, createdName=刘洋1981, createdTime=Mon Mar 14 08:03:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197628, encodeId=a631219e6286a, content=审稿速度:2.0 经验分享：这个杂志真不简单，三个审稿人都很严格，然后凉凉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b209147650, createdName=ms6000001986535996, createdTime=Tue Apr 09 17:03:13 CST 2024, time=2024-04-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2196036, encodeId=633821960367d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：经过了圣诞节，实际上可能只用了三周返回稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d46d8770670, createdName=ms3000000561056569, createdTime=Fri Mar 29 12:32:02 CST 2024, time=2024-03-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182220, encodeId=25432182220b5, content=偏重的研究方向：转化医学 经验分享：投稿后3天变成under review，中途日期变更了两次，但还是under review状态，这是什么原因呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8916149900, createdName=ms2000000395345853, createdTime=Wed Jan 17 16:28:01 CST 2024, time=2024-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154513, encodeId=fd122154513b5, content=偏重的研究方向：转化医学 经验分享：三天拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLaYGcq2jR8ySEWalFlEicicYzD5he3CJZ4qCCKibxsk54QPWpWyolIvG4cUgKOacP1B28qsAiarh5wOA/132, createdBy=277d2215936, createdName=dujiang, createdTime=Fri Aug 25 11:04:49 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省)]

2023-08-25 dujiang 来自河南省

偏重的研究方向：转化医学
经验分享：三天拒稿

131 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务